* known hypersensitivity or allergy to any component of the drug under evaluation * age under 18 years * use of immunosuppressants (including systemic corticosteroids) in the last 30 days * pregnant or lactating * patients with other acute infectious diseases * patients with autoimmune disease and/or chronic decompensated diseases * who have received a vaccine for covid-19 (1/2 dose) or that have taken ivermectin (prior to 30 days of the study) or who are participating in another covid-19 prophylaxis study

* known hypersensitivity or allergy to any component of the drug under evaluation * age under 18 years * use of immunosuppressants (including systemic corticosteroids) in the last 30 days * pregnant or lactating * patients with other acute infectious diseases * patients with autoimmune disease and/or chronic decompensated diseases * who have received a vaccine for covid-19 (1/2 dose) or that have taken ivermectin (prior to 30 days of the study) or who are participating in another covid-19 prophylaxis study

- known hypersensitivity or allergy to any component of the drug under evaluation - age under 18 years - use of immunosuppressants (including systemic corticosteroids) in the last 30 days - pregnant or lactating - patients with other acute infectious diseases - patients with autoimmune disease and/or chronic decompensated diseases - who have received a vaccine for covid-19 (1/2 dose) or that have taken ivermectin (prior to 30 days of the study) or who are participating in another covid-19 prophylaxis study

- known hypersensitivity or allergy to any component of the drug under evaluation - age under 18 years - use of immunosuppressants (including systemic corticosteroids) in the last 30 days - pregnant or lactating - patients with other acute infectious diseases - patients with autoimmune disease and/or chronic decompensated diseases - who have received a vaccine for covid-19 (1/2 dose) or that have taken ivermectin (prior to 30 days of the study) or who are participating in another covid-19 prophylaxis study